US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

39.37

-0.0843-0.21%

Volume:6K

Turnover:250.29K

Market Cap:7.87M

PE:- -

High:39.87

Open:39.87

Low:39.22

Close:39.46

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.82

T/O Rate:3.17%

Dividend:0.32

Dividend Rate:0.81%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

PICC P&C Issues China's First Invasive Brain-Computer Interface Surgery Accident Insurance

Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta

J.P. Morgan Remains a Buy on Xenon (XENE)

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Dianthus Therapeutics (DNTH)

Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)

Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

MT Newswires Live

Dianthus Therapeutics CEO Marino Garcia Reports Disposal of 166,000 Common Shares Worth $17.97 Million

Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date

MT Newswires Live

Scholar Rock Holdings Pulls Novo Nordisk Facility from Drug Application After FDA Flag

Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Scholar Rock Drops Catalent Indiana from Apitegromab BLA After FDA Flags Site Inspection as OAI

Scholar Rock Holding Corporation - to Remove Catalent Indiana Facility from Apitegromab Bla

THOMSON REUTERS

Scholar Rock Holding Corporation - Engaging with Ema to Include Second Fill-Finish Facility in Apitegromab Maa

THOMSON REUTERS

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch Immediately upon FDA Approval

THOMSON REUTERS

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (Bla) for Spinal Muscular Atrophy (Sma) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

THOMSON REUTERS

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/IBRN/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":39.3744,"timestamp":1788465600000,"preClose":39.4587,"halted":0,"volume":6342,"delay":0,"changeRate":-0.0021364109816085913,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0843,"latestTime":"09-04 09:29:42 EDT","open":39.87,"high":39.87,"low":39.22,"amount":250291,"amplitude":0.016473,"askPrice":45.53,"askSize":500,"bidPrice":37.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.3744,"sharesOutstanding":150000,"nav":39.408165,"aum":7881633,"dividendRate":0.008114,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.38,"preClose":39.3744,"latestTime":"16:10 EDT","volume":6,"amount":235.9776,"timestamp":1788466204933,"change":0.0056,"changeRate":0.000142,"amplitude":0},"volumeRatio":1.8220997165186916,"impliedVol":0.0707,"impliedVolPercentile":0.247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8220997165186916,"shares":200000,"dividePrice":0.3195,"high":39.87,"amplitude":0.016473,"preClose":39.4587,"low":39.22,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":39.3744,"committee":-0.996008,"eps":0,"divideRate":0.008114,"volume":6342,"delay":0,"ttmEps":0,"open":39.87,"prevYearClose":32.3193,"fiveDayClose":40.2953,"twentyDayClose":38.5746,"sixtyDayClose":34.7298},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1136280436","title":"PICC P&C Issues China's First Invasive Brain-Computer Interface Surgery Accident Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=1136280436","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136280436?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:08","pubTimestamp":1786504105,"startTime":"0","endTime":"0","summary":"On August 12, PICC Property and Casualty Company Limited, a subsidiary of People's Insurance Company (Group) of China Limited (01339), announced it has underwritten the country's first invasive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658468579","title":"Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658468579","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658468579?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:09","pubTimestamp":1786482556,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics SVP General Counsel Adam Veness melepas saham senilai USD 2,21 jutaSVP, General Counsel dan Secretary Adam M Veness melepas seluruh kepemilikan saham biasa Dianthus Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4W8dyv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics SVP General Counsel Adam Veness Melepas Saham Senilai USD 2,21 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658343990","title":"J.P. Morgan Remains a Buy on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658343990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658343990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:56","pubTimestamp":1786449382,"startTime":"0","endTime":"0","summary":"In a report released today, Tessa Romero from J.P. Morgan maintained a Buy rating on Xenon, with a price target of $82.00. Romero covers the Health...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0225283273.USD","LU0320765646.SGD","LU1244550221.USD","LU2133065610.SGD","IBRN","LU0795875086.SGD","LU1074936037.SGD","LU1548497426.USD","LU0106261372.USD","LU2089284900.SGD","LU0971096721.USD","BK4534","LU1791710400.SGD","LU1791710582.SGD","LU0210528500.USD","LU0795875169.SGD","LU2028103732.USD","LU1720051017.SGD","LU0106831901.USD","BK4588","LU2271345857.HKD","LU0882574139.USD","LU0912757837.SGD","LU2264538146.SGD","XENE","LU1720051108.HKD","IAI","LU0390134368.USD","LU2357305700.SGD","KBWB","LU2089283258.USD","LU1732799900.SGD","LU0053666078.USD","LU1363072403.SGD","BK4139","SBIO","IE00B775SV38.USD","LU1244550577.SGD","LU2023251221.USD","LU0314104364.USD","LU1668664300.SGD","LU0098860793.USD","LU1989772923.USD","BK4516","LU0158827781.USD","IE00B3S45H60.SGD","LU1244550494.USD","LU1064131342.USD","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966867","title":"Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Elanco Animal Health (ELAN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658966867?lang=en_us&edition=fundamental","pubTime":"2026-08-11 10:20","pubTimestamp":1786414812,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH), Elanco Animal Health (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-dianthus-therapeutics-dnth-elanco-animal-health-elan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-dianthus-therapeutics-dnth-elanco-animal-health-elan-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","BK4007","XLV","BK4588","BK4585","LU1941712264.USD","HCSG","DNTH","BK4137","LU1941712348.USD","ELAN","XBI","IBRN","LU0029874061.USD","BK4561","LU0128526141.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939006","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Dianthus Therapeutics (DNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939006","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939006?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:50","pubTimestamp":1786366208,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS) and Dianthus Therapeutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-and-dianthus-therapeutics-dnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-and-dianthus-therapeutics-dnth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HIMZ","GLAM","HMYY","BK4139","HIYY","HEAL","DNTH","IBRN","BK4196","THNR","HIMY","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658987680","title":"Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658987680","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658987680?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:14","pubTimestamp":1786356840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SRRK/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982377","title":"Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982377?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:40","pubTimestamp":1786354831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLAY","BK4588","SBIO","IBRN","LU0029874061.USD","BK4581","XENE","XBI","LABU","BK4139","BK4137","HCSG","BK4585","LU0128526141.USD","BK4563","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658347984","title":"Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2658347984","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658347984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:19","pubTimestamp":1786353580,"startTime":"0","endTime":"0","summary":"(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657193621","title":"Dianthus Therapeutics CEO Marino Garcia Reports Disposal of 166,000 Common Shares Worth $17.97 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657193621","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657193621?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:31","pubTimestamp":1786141877,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 millionDianthus Therapeutics CEO and President Marino Garcia reported option exercises and share sales on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLbvQy8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics CEO Marino Garcia Reports Disposal of 166,000 Common Shares Worth $17.97 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629325","title":"Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629325","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629325?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:46","pubTimestamp":1786135593,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding (SRRK) said the FDA review of its apitegromab Biologics License Application for spinal muscular atrophy remains on track for potential approval by the September 30 PDUFA date, wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","SRRK","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629331","title":"Scholar Rock Holdings Pulls Novo Nordisk Facility from Drug Application After FDA Flag","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629331","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629331?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:46","pubTimestamp":1786135560,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding is removing one Novo Nordisk-owned fill-finish facility from its biologics license application for apitegromab to treat spinal muscular atrophy, after the facility was flagged for possible enforcement by the Food and Drug Administration.The biopharmaceutical company said the application will proceed with a second fill-finish facility -- a U.S.-based facility in good standing with the FDA and European regulators -- and is on track for potential FDA approval by Sept. 30.Scholar Rock said it received a customer notification on Friday that the FDA classified the first fill-finish facility, Novo Nordisk-owned Catalent Indiana, as Official Action Indicated following an April site inspection. The classification means that regulatory and/or administrative actions are recommended, according to the FDA.\"Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA,\" the company said. \"FDA review","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","NVOH","BK4588","BK4585","NVO","LU1093756168.USD","IBRN","NVOX","OZEM","BK4532","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","THNR","BK4139","BK4007","PPH","SRRK","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657072626","title":"Scholar Rock to remove Catalent Indiana facility from apitegromab BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657072626","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657072626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134642,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA review of the apitegromab biologics license application, or BLA, for the treatment of children and adult...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-to-remove-catalent-indiana-facility-from-apitegromab-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-to-remove-catalent-indiana-facility-from-apitegromab-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","SRRK","THNR","BK4588","BK4585","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","BK4588","HCSG","BK4137","BK4196","LU0128526141.USD","GHRS","LFSC","BK4139","LABU","BK4007","THNR","BK4585","GNOM","BK4082","GNMX","INMD","LU0889565916.HKD","FFOX","HELX","PSIL","SRRK","PTH","IBRN","BK4535","LU0029874061.USD","LU0320765992.SGD","GDOC","EKG","BK4539","GH","XBI","LU0109394709.USD","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657673626","title":"Scholar Rock Drops Catalent Indiana from Apitegromab BLA After FDA Flags Site Inspection as OAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2657673626","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657673626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:21","pubTimestamp":1786134089,"startTime":"0","endTime":"0","summary":"Scholar Rock drops Catalent Indiana from apitegromab BLA after FDA flags site inspection as OAIScholar Rock’s FDA review of the apitegromab BLA for spinal muscular atrophy will proceed with only its s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDLbzqzQq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626616","title":"Scholar Rock Holding Corporation - to Remove Catalent Indiana Facility from Apitegromab Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626616?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THNR","IBRN","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619626","title":"Scholar Rock Holding Corporation - Engaging with Ema to Include Second Fill-Finish Facility in Apitegromab Maa","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THNR","SRRK","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657266176","title":"Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch Immediately upon FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657266176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657266176?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SRRK","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657162661","title":"Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (Bla) for Spinal Muscular Atrophy (Sma) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2657162661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657162661?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA25LRWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623471","title":"Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623471?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:00","pubTimestamp":1786129228,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oculis Holding (OCS) and Xenon (XENE) with bullish s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE","OCS","BK4139","SBIO","IBRN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628087","title":"Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628087","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628087?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:02","pubTimestamp":1786125732,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals'  recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","BK4139","XENE","LABU","BK4588","BK4585","SBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}